Erectile dysfunction (ED) is more common than most people think, yet it’s still a topic many shy away from discussing. The ...

Erectile dysfunction meds, like Viagra and Cialis, can help you get and keep an erection. However, each has different side effects, dosage schedules, and other factors. Here, we look at how they ...

One effective way to measure investment growth is CAGR. The Compound Annual Growth Rate, or CAGR, is a financial metric that measures the annual growth of an investment over a period of time.

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Here’s more about this ...

The move was a blow to companies like Hims & Hers that offer compounded versions of glucagon-like peptide-1 agonist weight loss medications. The company's stock fell 26% in early trading on ...

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...

Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients. Compounded GLP-1s are custom-made by compounding ...

Rangers center Vincent Trocheck reportedly broke his finger Monday during Team USA’s loss to Sweden in the 4 Nations Face-Off. He still played Thursday during their overtime loss to Canada in ...

Shares of Hims & Hers Health HIMS.N, which advertised its compounded versions of weight-loss drugs during the Super Bowl this month, plunged 22% to $52, on a day it announced the purchase of a ...

The FDA's move is bad news for manufacturers of compounded semaglutide and the telehealth companies that have built up a market selling cheaper alternatives to branded weight loss drugs.